| scholarly article | Q13442814 |
| P2093 | author name string | Perrin LH | |
| Smart J | |||
| Chizzolini C | |||
| Loche M | |||
| Richle R | |||
| Merkli B | |||
| P2860 | cites work | Lectin-like polypeptides of P. falciparum bind to red cell sialoglycoproteins | Q47976115 |
| The malaria merozoite surface: a 140,000 m.w. protein antigenically unrelated to other surface components on Plasmodium knowlesi merozoites. | Q47976551 | ||
| Saimiri sciureus (karyotype 14-7): an alternative experimental model of Plasmodium falciparum infection. | Q47976734 | ||
| Immunization of owl monkeys to Plasmodium falciparum with merozoites from cultures of a knobless clone | Q47976794 | ||
| Immunization against blood-stage rodent malaria using purified parasite antigens | Q47996405 | ||
| Isolate-specific S-antigen of Plasmodium falciparum contains a repeated sequence of eleven amino acids | Q48394125 | ||
| Surface proteins of schizont-infected erythrocytes and merozoites of Plasmodium falciparum | Q70221204 | ||
| Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 | Q25938983 | ||
| Differential sensitivity in vivo of lethal and nonlethal malarial parasites to endotoxin-induced serum factor | Q36332801 | ||
| Antigenic differences among isolates of Plasmodium falciparum demonstrated by monoclonal antibodies | Q36338811 | ||
| Antigenicity of the infected-erythrocyte and merozoite surfaces in Falciparum malaria | Q36343017 | ||
| Biosynthesis and processing of a Plasmodium falciparum schizont antigen recognized by immune serum and a monoclonal antibody. | Q36347118 | ||
| Surface alterations of erythrocytes in Plasmodium falciparum malaria. Antigenic variation, antigenic diversity, and the role of the spleen | Q36347647 | ||
| Protective Plasmodium knowlesi Mr 74,000 antigen in membranes of schizont-infected rhesus erythrocytes | Q36347983 | ||
| Immunity to Malarial Antigens on the Surface of Plasmodium falciparum-Infected Erythrocytes * | Q38892211 | ||
| Merozoite vaccination of douroucouli monkeys against falciparum malaria | Q38893266 | ||
| Malaria antigen-specific T-cell responsiveness during infection with Plasmodium falciparum | Q39465674 | ||
| Immunity to Asexual Erythrocytic Stages of Plasmodium Falciparum: Role of Defined Antigens in the Humoral Response1 | Q40102615 | ||
| Three species of polyoma virus tumor antigens share common peptides probably near the amino termini of the proteins | Q40196909 | ||
| Plasmodium falciparum in Culture: Use of Outdated Erythrocytes and Description of the Candle Jar Method | Q40821256 | ||
| Multispot immunofluorescence: a simple semi-automatic method of processing large numbers of tests | Q41228036 | ||
| An Effective Immunization of Experimental Monkeys Against a Human Malaria Parasite, Plasmodium falciparum | Q41276058 | ||
| Characterization of polypeptides made in vitro from bacteriophage lambda DNA. | Q43883736 | ||
| Evidence for a malaria mitogen in human malaria | Q44190673 | ||
| Interferon Induced by Plasmodium berghei | Q44250787 | ||
| Antigenic Diversity in the Human Malaria Parasite Plasmodium falciparum | Q47973891 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antimalarial | Q521616 |
| immunization | Q1415366 | ||
| P304 | page(s) | 441-451 | |
| P577 | publication date | 1984-08-01 | |
| P1433 | published in | Journal of Experimental Medicine | Q3186912 |
| P1476 | title | Antimalarial immunity in Saimiri monkeys. Immunization with surface components of asexual blood stages | |
| P478 | volume | 160 |
| Q47888235 | A hybrid gene to express protein epitopes from both sporozoite and merozoite surface antigens of Plasmodium falciparum |
| Q39387268 | A longitudinal study of naturally acquired cellular and humoral immune responses to a merozoite surface protein (MSP1) of Plasmodium falciparum in an area of seasonal malaria transmission. |
| Q34520456 | A prospective study of the association between the human humoral immune response to Plasmodium falciparum blood stage antigen gp190 and control of malarial infections. |
| Q46186627 | A rhoptry antigen of Plasmodium falciparum is protective in Saimiri monkeys |
| Q38890556 | Ability of recombinant or native proteins to protect monkeys against heterologous challenge with Plasmodium falciparum. |
| Q45760438 | Addition of the MSA1 signal and anchor sequences to the malaria merozoite surface antigen 1 C-terminal region enhances immunogenicity when expressed by recombinant vaccinia virus |
| Q36354328 | Allelic forms of gp195, a major blood-stage antigen of Plasmodium falciparum, are expressed in liver stages |
| Q38635546 | An update on candidate malaria vaccines |
| Q57083209 | Analysis of human t cell response to twoplasmodium falciparum merozoite surface antigens |
| Q45215361 | Antibody responses to a synthetic peptide-based malaria vaccine candidate: influence of sequence variants of the peptide |
| Q35272200 | Antigenic diversity and variation in blood stages of Plasmodium falciparum |
| Q39447157 | Antigens of Plasmodium falciparum blood stages with clinical interest cloned and expressed in E. coli |
| Q36489015 | Cloning and expression in Escherichia coli of a surface antigen of Plasmodium falciparum merozoites |
| Q40374219 | Conservation of antigen components from two recombinant hybrid proteins protective against malaria. |
| Q34120959 | Construction of a tetR-integrated Salmonella enterica serovar Typhi CVD908 strain that tightly controls expression of the major merozoite surface protein of Plasmodium falciparum for applications in human Vaccine production |
| Q33975652 | Current status of malaria and potential for control |
| Q41264979 | DNA vaccines against malaria: immunogenicity and protection in a rodent model |
| Q36799265 | Defined Plasmodium falciparum antigens in malaria serology. |
| Q40151008 | Epstein-Barr virus transformation of Saimiri sciureus (squirrel monkey) B cells and generation of a Plasmodium brasilianum-specific monoclonal antibody in P. brasilianum-infected monkeys |
| Q36488514 | Expression of Plasmodium falciparum surface antigens in Escherichia coli |
| Q41738501 | Expression of hybrid malaria antigens in insect cells and their engineering for correct folding and secretion |
| Q47924321 | Gene gun-based co-immunization of merozoite surface protein-1 cDNA with IL-12 expression plasmid confers protection against lethal Plasmodium yoelii in A/J mice. |
| Q34298109 | Generalized immunological recognition of the major merozoite surface antigen (gp195) of Plasmodium falciparum |
| Q37911988 | Genetic diversity in Plasmodium falciparum |
| Q67688118 | Glycolipid anchorage of plasmodium falciparum surface antigens |
| Q42005028 | Human-human hybridomas secreting monoclonal antibodies to the Mr 195,000 Plasmodium falciparum blood stage antigen |
| Q47905693 | Immunization against Plasmodium falciparum with recombinant polypeptides produced in Escherichia coli |
| Q33598899 | Immunization of Aotus monkeys with Plasmodium falciparum blood-stage recombinant proteins |
| Q34628596 | Immunization with a Plasmodium falciparum merozoite surface antigen induces a partial immunity in monkeys |
| Q89559305 | Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial |
| Q37406168 | Immunization with synthetic peptides of a Plasmodium falciparum surface antigen induces antimerozoite antibodies |
| Q33608668 | Immunogenicity of the Plasmodium falciparum serine repeat antigen (p126) expressed by vaccinia virus. |
| Q33605280 | Immunological cross-reactivity of the C-terminal 42-kilodalton fragment of Plasmodium falciparum merozoite surface protein 1 expressed in baculovirus |
| Q44788262 | Induction and displacement of an helix in the 6725 SERA peptide analogue confers protection against P. falciparum malaria |
| Q40166654 | Induction of protective immunity to Plasmodium falciparum in Saimiri sciureus monkeys with partially purified exoantigens |
| Q40171693 | Induction of protective immunity to monoclonal-antibody-defined Plasmodium falciparum antigens requires strong adjuvant in Aotus monkeys. |
| Q48055998 | Interallelic recombination in the merozoite surface protein 1 (MSP-1) gene of Plasmodium vivax from Thai isolates |
| Q68191266 | Isolation and characterization of the 80,000 dalton Plasmodium falciparum merozoite surface antigen |
| Q47911842 | Limiting dilution assay for human B cells based on their activation by mutant EL4 thymoma cells: total and antimalaria responder B cell frequencies |
| Q39228943 | Longitudinal study of Plasmodium falciparum polymorphic antigens in a malaria-endemic population |
| Q94464389 | Low-Complexity Repetitive Epitopes of Plasmodium falciparum Are Decoys for Humoural Immune Responses |
| Q41090784 | Major surface antigen p190 of Plasmodium falciparum: detection of common epitopes present in a variety of plasmodia isolates |
| Q37657392 | Malaria vaccine |
| Q36641624 | Malaria vaccine development |
| Q37029523 | Malarial proteases and host cell egress: an 'emerging' cascade |
| Q57252776 | Malarial proteinase? |
| Q38674929 | Mechanisms of immunity to malaria and the possibilities of a blood-stage vaccine: a critical appraisal |
| Q40055186 | Merozoite Surface Protein 1 from Plasmodium falciparum Is a Major Target of Opsonizing Antibodies in Individuals with Acquired Immunity against Malaria |
| Q34620173 | Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria |
| Q35519418 | NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria |
| Q40734085 | Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. |
| Q34541366 | Naturally acquired human antibodies which recognize the first epidermal growth factor-like module in the Plasmodium falciparum merozoite surface protein 1 do not inhibit parasite growth in vitro |
| Q37896256 | Plasmodium falciparum serine repeat antigen 5 (SE36) as a malaria vaccine candidate |
| Q39672357 | Plasmodium falciparum serine repeat protein, a new target of monocyte-dependent antibody-mediated parasite killing |
| Q36349756 | Polymorphism of a high molecular weight schizont antigen of the human malaria parasite Plasmodium falciparum |
| Q41434381 | Polymorphism of the precursor for the major surface antigens of Plasmodium falciparum merozoites: studies at the genetic level |
| Q35776265 | Preferential binding of Plasmodium falciparum SERA and rhoptry proteins to erythrocyte membrane inner leaflet phospholipids. |
| Q47902824 | Primary structure of the precursor to the three major surface antigens of Plasmodium falciparum merozoites |
| Q40146914 | Protection of Aotus monkeys from malaria infection by immunization with recombinant hybrid proteins |
| Q44432998 | Protective immune responses against protease-like antigens of the murine malaria parasite Plasmodium vinckei |
| Q33596771 | Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: adjuvant effects on induction of protective immunity. |
| Q40150136 | Protective immunity induced in Aotus monkeys by recombinant SERA proteins of Plasmodium falciparum |
| Q36394182 | Recent advances in recombinant protein-based malaria vaccines |
| Q36404193 | Recombinant Mycobacterium bovis bacillus Calmette-Guérin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies |
| Q36943106 | Roles of conserved and allelic regions of the major merozoite surface protein (gp195) in immunity against Plasmodium falciparum |
| Q47867845 | Serine repeat antigen peptides which bind specifically to red blood cells |
| Q35383761 | Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum |
| Q33772752 | Solution structure of a Plasmodium falciparum AMA-1/MSP 1 chimeric protein vaccine candidate (PfCP-2.9) for malaria |
| Q35226199 | Splenic architecture disruption and parasite-induced splenocyte activation and anergy in Plasmodium falciparum-infected Saimiri sciureus monkeys |
| Q69566223 | Status of malaria vaccine research |
| Q39075264 | Steps towards a malaria vaccine |
| Q44274141 | Structural diversity of Plasmodium falciparum gp200 is detected by T cells |
| Q38349458 | Studies on glycoproteins in the human malaria parasite Plasmodium falciparum--lectin binding properties and the possible carbohydrate-protein linkage |
| Q39086032 | Synthetic low-toxicity muramyl dipeptide and monophosphoryl lipid A replace Freund complete adjuvant in inducing growth-inhibitory antibodies to the Plasmodium falciparum major merozoite surface protein, gp195. |
| Q48002598 | Synthetic peptides based on conserved Plasmodium falciparum antigens are immunogenic and protective against Plasmodium yoelii malaria |
| Q37483845 | The 3' portion of the gene for a Plasmodium yoelii merozoite surface antigen encodes the epitope recognized by a protective monoclonal antibody |
| Q38163224 | The Wellcome Trust lecture. Genes for antigens of Plasmodium falciparum |
| Q40910243 | The development of a multivalent DNA vaccine for malaria |
| Q36791080 | Third form of the precursor to the major merozoite surface antigens of Plasmodium falciparum |
| Q36097561 | Variation in the gene encoding a major merozoite surface antigen of the human malaria parasite Plasmodium falciparum |
| Q36636738 | Where Are We in the Quest for Vaccines for Malaria? |
Search more.